Dyadic International (NASDAQ:DYAI) Shares Pass Below 50 Day Moving Average – What’s Next?

Dyadic International Inc. (NASDAQ:DYAI)’s stock price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.78 and traded as low as $0.7550. Dyadic International shares last traded at $0.8486, with a volume of 166,010 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $3.00.

Dyadic International Price Performance

The company’s fifty day moving average price is $0.78 and its 200 day moving average price is $0.84. The company has a market capitalization of $28.50 million, a P/E ratio of -3.40 and a beta of 1.17. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The company had revenue of $1.11 million during the quarter, compared to the consensus estimate of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. As a group, sell-side analysts forecast that Dyadic International Inc. will post 0.13 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Bank of America Corp DE lifted its position in Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares during the period. Marathon Capital Management bought a new position in Dyadic International in the 3rd quarter valued at about $41,000. Geode Capital Management LLC raised its position in shares of Dyadic International by 13.7% in the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new position in shares of Dyadic International in the 3rd quarter valued at approximately $190,000. Finally, Apis Capital Advisors LLC bought a new stake in shares of Dyadic International during the 3rd quarter worth approximately $1,817,000. Institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.